Smith Paul W, Zuccotto Fabio, Bates Robert H, Martinez-Martinez Maria Santos, Read Kevin D, Peet Caroline, Epemolu Ola
Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, School of Life Sciences , University of Dundee , Dow Street , Dundee . DDI 5EH , U.K.
Global Health R&D , GlaxoSmithKline , Calle Severo Ochoa 2 , 28760 Tres Cantos , Madrid , Spain.
ACS Infect Dis. 2018 Oct 12;4(10):1439-1447. doi: 10.1021/acsinfecdis.8b00160. Epub 2018 Sep 10.
β-Lactams represent perhaps the most important class of antibiotics yet discovered. However, despite many years of active research, none of the currently approved drugs in this class combine oral activity with long duration of action. Recent developments suggest that new β-lactam antibiotics with such a profile would have utility in the treatment of tuberculosis. Consequently, the historical β-lactam pharmacokinetic data have been compiled and analyzed to identify possible directions and drug discovery strategies aimed toward new β-lactam antibiotics with this profile.
β-内酰胺类抗生素或许是迄今已发现的最重要的一类抗生素。然而,尽管经过多年的积极研究,该类目前已获批的药物中尚无一种兼具口服活性和长效作用。近期的研究进展表明,具有这种特性的新型β-内酰胺类抗生素在结核病治疗中会有应用价值。因此,已对β-内酰胺类抗生素的历史药代动力学数据进行了汇总和分析,以确定针对具有这种特性的新型β-内酰胺类抗生素的可能方向和药物研发策略。